There is encouraging news for patients with endometrial cancer based on the results of two recent phase 3 clinical trials: Immunotherapy combined with chemotherapy may appreciably increase progression-free survival for patients with advanced or recurrent endometrial cancer.

Both trials—NRG-GY018 and RUBY— were presented at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer in Tampa, Florida. Both also appear in The New England Journal of Medicine.

“Both the dostarlimab- and pembrolizumab-containing trials [RUBY and NRG-GY018, respectively] are major advances for the therapy of women with metastatic endometrial cancer,” says Gini Fleming, MD, professor of medicine in the Department of Medicine at the University of Chicago in Chicago, Illinois, who was not directly involved with either study. “It’s important to note that the trials are similar and complement and confirm each other.”

中文翻译：

---

在化疗中加入免疫疗法可提高子宫内膜癌患者的生存率

根据最近两项3期临床试验的结果，对于子宫内膜癌患者来说，有一个令人鼓舞的消息：免疫疗法联合化疗可能会明显增加晚期或复发性子宫内膜癌患者的无进展生存期。

NRG-GY018 和 RUBY 这两项试验均在佛罗里达州坦帕举行的妇科肿瘤学会 2023 年女性癌症年会上发表。两者也出现在《新英格兰医学杂志》上。

“含有多斯塔利单抗和派姆单抗的试验[分别为 RUBY 和 NRG-GY018] 都是治疗患有转移性子宫内膜癌的女性的重大进展，”该大学医学系医学教授 Gini Fleming 医学博士说伊利诺伊州芝加哥市的芝加哥大学教授，他没有直接参与这两项研究。“值得注意的是，这些试验是相似的，并且相互补充和证实。”